Table 2.
Univariable and multivariate analysis of treatment-free survival in 191 patients with chronic lymphocytic leukemia
| Characteristic | Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age > 65 yr | 1.089 (0.757-1.568) | 0.645 | ND | ND |
| Binet ≥ stage B | 2.747 (1.836-4.110) | < 0.001a) | 2.012 (1.302-3.109) | 0.002a) |
| β2-MG > 3.5 mg/L | 2.734 (1.904-3.927) | < 0.001a) | 2.023 (1.367-2.993) | < 0.001a) |
| CD38 (> 30%) | 1.507 (1.003-2.262) | 0.048a) | 1.274 (0.837-1.939) | 0.259 |
| ZAP-70 (> 20%) | 1.168 (0.819-1.668) | 0.391 | ND | ND |
| TP53 disruption | 1.633 (1.079-2.471) | 0.020a) | 1.237 (0.799-1.916) | 0.339 |
| IGHV unmutated | 1.439 (1.009-2.052) | 0.045a) | 1.038 (0.709-1.519) | 0.848 |
| AFR ≤ 9.7 | 1.237 (0.720-2.126) | 0.440 | ND | ND |
HR, hazard ratio; CI, confidence interval; ND, not done; β2-MG, β2-microglobulin; TP53, tumor protein 53; IGHV, immunoglobulin heavy variable-region; AFR, albumin-to-fibrinogen ratio.
a)
Statistically significant.